【摘要】 目的:评价预激CAG方案对老年急性髓系白血病的疗效和不良反应。方法:20例老年白血病患者给予阿克拉霉素(Acla)10mg/d,静脉滴注,每日一次,d1～d7;阿糖胞苷(Ara-c)30mg/d,分两次皮下注射(10mg/m2·d),每12小时一次,d1～d14;粒细胞集落刺激因子(G-CSF)300/d(200μg/m2·d),皮下注射,每日一次,d1～d14。化疗过程中白细胞>30×109/L时,停用G-CSF,出现IV度骨髓抑制时停止化疗。同时监测血常规、肝肾功能和心电图。结果:1疗程完全缓解(CR)率40%,2疗程后总CR率50%,总有效率达65%。发生Ⅳ度骨髓抑制者9例,7例发生Ⅳ度骨髓抑制者出现轻中度感染。消化道不良反应发生率40%,肝功能异常5例,尿素氮轻度升高4例。结论:预激CAG方案对老年急性髓系白血病疗效好,副作用低。更多还原

【Abstract】 Objective: To evaluate the efficacy and side-effect of priming regimen CAG on elderly acute myeloid leukemia(AML). Methods: 20 AML patients were treated with CAG regimen consisting of aclarubicin (Acla, 10 mg/d, d1～d7, intravenously),cytarabine(Ara-c 10 mg/m2, q12h, d1～d14, subcutaneously) and granulocyte colony-stimulating factor(G-CSF, 200 μg/m2·d, d1～d14, subcutaneously). G-CSF was suspended when white blood cell count beyond 30×109/L. Chemotherapy was suspended when Ⅳ degree myelosupression appeared. Blood routine examination, liver and function, electrocardiogram were monitored. Results: 40% patients achieved complete remission(CR) after first period of chemotherapy, 50% patients achieved CR after second period of chemotherapy. The overall CR ratio was 65%. The ratio of gstrointestinal side-effect was 40%. Ⅳ degree myelosupression occurred in 9 cases with 7 of them suffer from infection, and liver function in 5 cases, urea nitrogen increasing in 4 cases. Conclusion: The priming regimen CAG is effective and low-side-effect in treatment of elderly acute myeloid leukemia.更多还原